Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Richard J Marrero, Deedra Nicolet, Vivek M. Shastri, Krzysztof Mrózek, Christopher J. Walker, William Blum, Bayard L Powell, Jonathan E Kolitz, Joseph O Moore, Geoffrey L Uy, Wendy Stock, Andrew J Carroll, John C. Byrd, Ann-Kathrin Eisfeld, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 2954.

https://doi.org/10.1182/blood-2023-187361

Published: 2023

Journal Articles

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Blood (2022) 140 (Supplement 1): 936–939.

https://doi.org/10.1182/blood-2022-165395

Published: 2022

Journal Articles

Genomic Integration of Adult and Pediatric Acute Myeloid Leukemia Reveals Age Dependent Risk Association

Maarten Fornerod, Deedra Nicolet, Krzysztof Mrózek, Jonathan E. Kolitz, William G. Blum, Joseph O. Moore, Robert James Mayer, Richard M. Stone, Geoffrey L. Uy, Wendy Stock, John C. Byrd, Ann-Kathrin Eisfeld, Tanja A. Gruber

Blood (2022) 140 (Supplement 1): 9165–9166.

https://doi.org/10.1182/blood-2022-160470

Published: 2022

Journal Articles

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Blood (2021) 138 (Supplement 1): 221.

https://doi.org/10.1182/blood-2021-151072

Published: 2021

Journal Articles

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Blood (2021) 138 (Supplement 1): 685.

https://doi.org/10.1182/blood-2021-153015

Published: 2021

Journal Articles

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Kathryn E Flynn, PhD, Kevin P. Weinfurt, PhD, Li Lin, MS, Jerald P. Radich, MD, Charles A. Schiffer, MD, Michael J. Mauro, MD, Javier Pinilla Ibarz, MD PhD, Joseph O. Moore, MD, Richard A. Larson, MD, Vivian G. Oehler, MD, Michael W. Deininger, James E. Thompson, MD, Neil P Shah, MD PhD, Martha Wadleigh, MD, Ellen K. Ritchie, MD, Richard T. Silver, MD, Jorge E. Cortes, MD, Vamsi Kota, Ehab L. Atallah, MD

Blood (2019) 134 (Supplement_1): 705.

https://doi.org/10.1182/blood-2019-126002

Published: 2019

Journal Articles

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Blood (2018) 132 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2018-99-114589

Published: 2018

Journal Articles

Results from the U.S. Life after Stopping TKIs (LAST) Study

Blood (2017) 130 (Supplement 1): 2903.

https://doi.org/10.1182/blood.V130.Suppl_1.2903.2903

Published: 2017

Journal Articles

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Danielle M. Brander, MD, Anne W Beaven, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Cristina Gasparetto, MD, Thomas C. Shea, MD, Carlos deCastro, Joseph O. Moore, MD, David A. Rizzieri, MD

Blood (2012) 120 (21): 1626.

https://doi.org/10.1182/blood.V120.21.1626.1626

Published: 2012

Journal Articles

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Arati Rao, MD, David A. Rizzieri, MD, Eduardo Vanegas, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4948.

https://doi.org/10.1182/blood.V120.21.4948.4948

Published: 2012

Journal Articles

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

Arati Rao, MD, Ghazi Khan, David A. Rizzieri, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Donna Adams, RN, Julie Warzecho, RN, Carlos Decastro, MD

Blood (2012) 120 (21): 4935.

https://doi.org/10.1182/blood.V120.21.4935.4935

Published: 2012

Journal Articles

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

Blood (2012) 120 (2): 249–258.

https://doi.org/10.1182/blood-2012-02-408492

Published: 2012

Includes: Supplemental data

Journal Articles

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

Blood (2011) 118 (26): 6920–6929.

https://doi.org/10.1182/blood-2011-08-368225

Published: 2011

Includes: Supplemental data

Journal Articles

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Anne W Beaven, MD, David A. Rizzieri, MD, Zachary Powell, Zhiguo Li, PhD, Peggy Alton, RN, Julie Warzecho, RN, Louis F. Diehl, MD, Joseph O. Moore, MD, Carlos Manuel de Castro, III, MD, Jon P. Gockerman, MD

Blood (2011) 118 (21): 2681.

https://doi.org/10.1182/blood.V118.21.2681.2681

Published: 2011

Journal Articles

Poor Outcome of RUNX1 -Mutated ( RUNX1 -mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,

Blood (2011) 118 (21): 3454.

https://doi.org/10.1182/blood.V118.21.3454.3454

Published: 2011

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Carlos Manuel de Castro, III, MD, Donna Adams, RN, Arati V Rao, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Julie Warzecho, RN, David A. Rizzieri, MD

Blood (2011) 118 (21): 5029.

https://doi.org/10.1182/blood.V118.21.5029.5029

Published: 2011

Journal Articles

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category

Blood (2011) 118 (21): 417.

https://doi.org/10.1182/blood.V118.21.417.417

Published: 2011

Journal Articles

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

Blood (2011) 118 (21): 414.

https://doi.org/10.1182/blood.V118.21.414.414

Published: 2011

NARROW

Impact of Cytarabine Pharmacogenomics on Survival of Adolescent and Young Adults with AML and Its Clinical Relevance in Black Patients

Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Genomic Integration of Adult and Pediatric Acute Myeloid Leukemia Reveals Age Dependent Risk Association

High Early Death Rates, Treatment Resistance and Short Survival of Black Adolescent and Young Adults (AYAs) with Acute Myeloid Leukemia (AML) (Alliance)

Multi-Dimensional Analysis of Adult Acute Myeloid Leukemia (AML) Landscape Cross-Continents Reveals Age Associated Trends in Mutations and Outcomes

Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia

Patients' Perspectives on the Definition of Cure in Chronic Myeloid Leukemia: A US Based Survey

Results from the U.S. Life after Stopping TKIs (LAST) Study

Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma

Pilot Study of Sorafenib for Myelodysplastic Syndrome

Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category

High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma

Poor Outcome of RUNX1 -Mutated ( RUNX1 -mut) Patients (Pts) with Primary, Cytogenetically Normal Acute Myeloid Leukemia (CN-AML) and Associated Gene- and MicroRNA (miR) Expression Signatures,

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

ASXL1 Mutations Identify a High-Risk Subgroup of Older Patients with Primary Cytogenetically Normal Acute Myeloid Leukemia within the European LeukemiaNet ‘Favorable' Genetic Category

Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only